Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Viridian Therapeutics' Lumvoa (veligrotug-vvze) received FDA approval for thyroid eye disease regardless of disease activity — the first approved TED therapy covering both active and chronic disease. Phase 3 THRIVE data showed 70% proptosis response vs 5% placebo.
In silico clinical trials and digital twin platforms are cutting drug development timelines in half as the FDA begins accepting computational evidence alongside traditional clinical data.
A $400 Apple Watch sensor can now estimate biological age with 2.4 years of error. The PpgAge study, Fountain Life, and ARPA-H are turning wearable data into a longevity diagnostic.
A Zurich-based neurotech startup raised a $2M pre-seed to build the first platform for longitudinal, personalised brain health monitoring, backed by Redstone, Concept Ventures, and Octopus.
FDA approved Tregzi, the first regulatory T cell therapy for allogeneic stem cell transplant in blood cancers. The Phase 3 Precision-T trial cut chronic GVHD by 74% — 78% cGVHD-free survival at 12 months vs 38% with conventional transplant.
SPRIND Orbital Bioworks challenge closes July 3 with €1.65M prize pool. WFIRM sends 3D bioprinted liver to ISS. Varda, Starlab, and Axiom build orbital bioprocessing infrastructure.
Insitro has raised 100M to build TherML, a modality-agnostic AI engine for drug discovery. Early pharma validation from Lilly and BMS.
Deep tech now accounts for 36% of global venture capital, up from 12% in 2016 — a structural reallocation driven by AI infrastructure, defense tech, and bioconvergence.
Get daily updates on the technologies and investment opportunities shaping the next decade — from AI infrastructure and autonomous systems to biotech, space, and defence. Curated analysis, no noise.
